Literature DB >> 12117418

Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.

Anna C Cunningham1, Karen A Hasty, Jan J Enghild, Alan E Mast.   

Abstract

Vascular injury results in the activation of coagulation and the release of proteolytic enzymes from neutrophils and connective- tissue cells. High concentrations of these inflammatory proteinases may destroy blood coagulation proteins, contributing to coagulation and bleeding disorders associated with severe inflammation. Matrix metalloproteinase-8 (MMP-8) is released from neutrophils at sites of inflammation and vascular disease. We have investigated the effect of MMP-8 degradation on the anticoagulant function of tissue factor pathway inhibitor (TFPI) as a potential pathological mechanism contributing to coagulation disorders. MMP-8 cleaves TFPI following Ser(174) within the connecting region between the second and third Kunitz domains ( k (cat)/ K (m) approximately 75 M(-1).s(-1)) as well as following Lys(20) within the NH(2)-terminal region. MMP-8 cleavage of TFPI decreases the anticoagulant activity of TFPI in factor Xa initiated clotting assays as well as the ability of TFPI to inhibit factor Xa in amidolytic assays. Yet, MMP-8 cleavage does not alter the ability of TFPI to inhibit trypsin. Since the inhibition of both factor Xa and trypsin is mediated by binding to the second Kunitz domain, these results suggest that regions of TFPI other than the second Kunitz domain may directly interact with factor Xa. (125)I-factor Xa ligand blots of TFPI fragments generated following MMP-8 degradation were used for probing binding interactions between factor Xa and regions of TFPI, other than the second Kunitz domain. In experiments performed under reducing conditions that disrupt the Kunitz domain structure, (125)I-factor Xa binds to the C-terminal fragment of MMP-8-degraded TFPI. This fragment contains portions of TFPI distal to Ser(174), which include the third Kunitz domain and the basic C-terminal region. An altered form of TFPI lacking the third Kunitz domain, but containing the C-terminal region, was used to demonstrate that the C-terminal region directly interacts with factor Xa.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117418      PMCID: PMC1222898          DOI: 10.1042/BJ20020696

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

Review 1.  Regulation of coagulation by a multivalent Kunitz-type inhibitor.

Authors:  G J Broze; T J Girard; W F Novotny
Journal:  Biochemistry       Date:  1990-08-21       Impact factor: 3.162

2.  Secreted forms of human neutrophil collagenase.

Authors:  K A Hasty; M S Hibbs; A H Kang; C L Mainardi
Journal:  J Biol Chem       Date:  1986-04-25       Impact factor: 5.157

3.  Structure-function relationship of human neutrophil collagenase: identification of regions responsible for substrate specificity and general proteinase activity.

Authors:  T Hirose; C Patterson; T Pourmotabbed; C L Mainardi; K A Hasty
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

4.  The effect of leukocyte elastase on tissue factor pathway inhibitor.

Authors:  D A Higuchi; T C Wun; K M Likert; G J Broze
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

5.  Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.

Authors:  R Wesselschmidt; K Likert; T Girard; T C Wun; G J Broze
Journal:  Blood       Date:  1992-04-15       Impact factor: 22.113

6.  SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages.

Authors:  S M Wilhelm; I E Collier; B L Marmer; A Z Eisen; G A Grant; G I Goldberg
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

7.  Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin).

Authors:  A E Mast; J J Enghild; H Nagase; K Suzuki; S V Pizzo; G Salvesen
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

8.  Effect of leukocyte proteinases on tissue factor pathway inhibitor.

Authors:  L C Petersen; S E Bjørn; O Nordfang
Journal:  Thromb Haemost       Date:  1992-05-04       Impact factor: 5.249

9.  Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor.

Authors:  T J Girard; L A Warren; W F Novotny; K M Likert; S G Brown; J P Miletich; G J Broze
Journal:  Nature       Date:  1989-04-06       Impact factor: 49.962

10.  Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains.

Authors:  T C Wun; K K Kretzmer; T J Girard; J P Miletich; G J Broze
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

View more
  16 in total

1.  Tissue dual RNA-seq allows fast discovery of infection-specific functions and riboregulators shaping host-pathogen transcriptomes.

Authors:  Aaron M Nuss; Michael Beckstette; Maria Pimenova; Carina Schmühl; Wiebke Opitz; Fabio Pisano; Ann Kathrin Heroven; Petra Dersch
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

2.  C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules.

Authors:  Praveen Papareddy; Martina Kalle; Gopinath Kasetty; Matthias Mörgelin; Victoria Rydengård; Barbara Albiger; Katarina Lundqvist; Martin Malmsten; Artur Schmidtchen
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

Review 3.  MMP induction and inhibition in myocardial infarction.

Authors:  Merry L Lindsey
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

4.  Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding.

Authors:  Georgina S Butler; Richard A Dean; Eric M Tam; Christopher M Overall
Journal:  Mol Cell Biol       Date:  2008-05-27       Impact factor: 4.272

5.  Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity.

Authors:  Julie A Bastarache; Ling Wang; Zhengming Wang; Kurt H Albertine; Michael A Matthay; Lorraine B Ware
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-02-29       Impact factor: 5.464

Review 6.  Biology of tissue factor pathway inhibitor.

Authors:  Jeremy P Wood; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

7.  Tissue factor pathway inhibitor is an inhibitor of factor VII-activating protease.

Authors:  F Stephan; I Dienava-Verdoold; I Bulder; D Wouters; A E Mast; H Te Velthuis; L A Aarden; S Zeerleder
Journal:  J Thromb Haemost       Date:  2012-06       Impact factor: 5.824

Review 8.  Alternatively spliced tissue factor pathway inhibitor: functional implications.

Authors:  Alan E Mast
Journal:  Front Biosci (Schol Ed)       Date:  2011-06-01

Review 9.  New insights into the biology of tissue factor pathway inhibitor.

Authors:  S A Maroney; A E Mast
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

10.  Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice.

Authors:  S A Maroney; J P Ferrel; S Pan; T A White; R D Simari; J H McVey; A E Mast
Journal:  J Thromb Haemost       Date:  2009-04-24       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.